search
Back to results

Braining: Implementation of Physical Exercise for Patients in Specialist Psychiatry

Primary Purpose

Mental Disorders

Status
Recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Braining
Structured advice on physical activity
Sponsored by
Region Stockholm
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mental Disorders focused on measuring physical exercise, mental disorders

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patient at one of the psychiatric units Exclusion Criteria: Physically active with moderate to vigorous physical activity above recommendations from World Health Organization (WHO) during the last 4 weeks Severe mental disorder such as ongoing mania, psychosis, and conditions when high risk of suicide or high risk of violence available according to the assessment of psychiatric staff at the unit. Medical conditions such as heart or lung disease, infection, withdrawal, where heart rate-increasing physical activity is considered contraindicated due to Medical reasons. Physical disability that makes it impossible to move independently to the gym and performing the indicated exercise in the training sessions. Mental disability which means that you can not participate in group training. Difficulty speaking or understanding the Swedish language. Ongoing heavy substance use.

Sites / Locations

  • Region Stockholm, Psykiatri Sydväst (Psychiatric Clinic Psychiatry Southwest)
  • AndreashusetRecruiting
  • Läkemedel och hälsa
  • Region Stockholm, Liljeholmsberget

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Braining

Structured advice on physical activity

Arm Description

A 12 week program where participants are encouraged to participate in physical exercise at the psychiatric unit.

Health interview and a 12 week program where participants are encouraged to engage in physical exercise outside the psychiatric setting.

Outcomes

Primary Outcome Measures

Physical activity
Objectively measured physical activity. Total physical activity measured in accelerometer-counts and translated into minutes/day spent in inactivity, low, moderate and vigorous intensity.
Patient Health Questionnaire 9 (PHQ-9)
Self rated depressive symptoms. Minimum value 0, maximum value 27, where higher values indicate more depressive symptoms.

Secondary Outcome Measures

Physical activity
Objectively measured physical activity. Total physical activity measured in accelerometer-counts and translated into minutes/day spent in inactivity, low, moderate and vigorous intensity.
Physical activity
Objectively measured physical activity. Total physical activity measured in accelerometer-counts and translated into minutes/day spent in inactivity, low, moderate and vigorous intensity.
Self reported physical activity
Self-reported physical activity: Total physical activity as Metabolic Energy Turnover (MET)hours/week and three level categories (low, moderate and high).
Self reported physical activity
Self-reported physical activity: Total physical activity as Metabolic Energy Turnover (MET)hours/week and three level categories (low, moderate and high).
Self reported physical activity
Self-reported physical activity: Total physical activity as Metabolic Energy Turnover (MET)hours/week and three level categories (low, moderate and high).
Patient Health Questionnaire 9 (PHQ-9)
Self rated depressive symptoms. Minimum value 0, maximum value 27, where higher values indicate more depressive symptoms.
Patient Health Questionnaire 9 (PHQ-9)
Self rated depressive symptoms. Minimum value 0, maximum value 27, where higher values indicate more depressive symptoms.
Generalised Anxiety Disorder 7-item scale (GAD-7)
Self rated anxiety symptoms. Minimum value 0, maximum value 21, where higher values indicate more anxiety symptoms.
Generalised Anxiety Disorder 7-item scale (GAD-7)
Self rated anxiety symptoms. Minimum value 0, maximum value 21, where higher values indicate more anxiety symptoms.
Generalised Anxiety Disorder 7-item scale (GAD-7)
Self rated anxiety symptoms. Minimum value 0, maximum value 21, where higher values indicate more anxiety symptoms.
Insomnia Severity Index (ISI)
Self rated insomnia symptoms. Minimum value 0, maximum value 28, where higher values indicate more insomnia symptoms.
Insomnia Severity Index (ISI)
Self rated insomnia symptoms. Minimum value 0, maximum value 28, where higher values indicate more insomnia symptoms.
Insomnia Severity Index (ISI)
Self rated insomnia symptoms. Minimum value 0, maximum value 28, where higher values indicate more insomnia symptoms.
The Work and Social Adjustment Scale (WSAS)
The WSAS is a simple, reliable and valid measure of impaired functioning. It is a sensitive and useful outcome measure offering the potential for readily interpretable comparisons across studies and disorders. The maximum score of the WSAS is 40, lower scores are better. The 5 items are scored 0-8 ranging from Not at-all-Slightly-Definitely-Markedly-Very-severely
The Work and Social Adjustment Scale (WSAS)
The WSAS is a simple, reliable and valid measure of impaired functioning. It is a sensitive and useful outcome measure offering the potential for readily interpretable comparisons across studies and disorders. The maximum score of the WSAS is 40, lower scores are better. The 5 items are scored 0-8 ranging from Not at-all-Slightly-Definitely-Markedly-Very-severely
The Work and Social Adjustment Scale (WSAS)
The WSAS is a simple, reliable and valid measure of impaired functioning. It is a sensitive and useful outcome measure offering the potential for readily interpretable comparisons across studies and disorders. The maximum score of the WSAS is 40, lower scores are better. The 5 items are scored 0-8 ranging from Not at-all-Slightly-Definitely-Markedly-Very-severely
EUROQOL 5 dimensions (EQ5D)
The EQ-5D [1] is an instrument that consists of two parts and measures health-related quality of life, regardless of disease profile. The instrument measures the general state of health within five dimensions. Values are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead. An EQ-5D value is also sometimes known as an 'index', 'score' or 'utility'.
EUROQOL 5 dimensions (EQ5D)
The EQ-5D [1] is an instrument that consists of two parts and measures health-related quality of life, regardless of disease profile. The instrument measures the general state of health within five dimensions. Values are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead. An EQ-5D value is also sometimes known as an 'index', 'score' or 'utility'.
EUROQOL 5 dimensions (EQ5D)
The EQ-5D [1] is an instrument that consists of two parts and measures health-related quality of life, regardless of disease profile. The instrument measures the general state of health within five dimensions. Values are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead. An EQ-5D value is also sometimes known as an 'index', 'score' or 'utility'.
Quality Adjusted Life Years (QALY)
The quality-adjusted life year (QALY) is a generic measure of disease burden, including both the quality and the quantity of life lived. It is used in economic evaluation to assess the value of medical interventions. One QALY equates to one year in perfect health. QALY scores range from 1 (perfect health) to 0 (dead).
The incremental cost-effectiveness (ICER)
The incremental cost-effectiveness ratio (ICER) is a statistic used in cost-effectiveness analysis to summarise the cost-effectiveness of a health care intervention. It is defined by the difference in cost between two possible interventions, divided by the difference in their effect. It represents the average incremental cost associated with 1 additional unit of the measure of effect. Costs will be described in monetary units, while effects will be measured in terms of health status.
Blood pressure
systolic and diastolic, mmHg
Blood pressure
systolic and diastolic, mmHg
Blood pressure
systolic and diastolic, mmHg
Body mass index (BMI)
Weight in kg divided by the square of height in m
Body mass index (BMI)
Weight in kg divided by the square of height in m
Body mass index (BMI)
Weight in kg divided by the square of height in m
Waist circumference
Waist circumference, cm
Waist circumference
Waist circumference, cm
Waist circumference
Waist circumference, cm
Heart rate (HR)
Heart rate, beats per minute, resting state
Heart rate (HR)
Heart rate, beats per minute, resting state
Heart rate (HR)
Heart rate, beats per minute, resting state
fasting blood sugar (FBS)
fasting blood sugar, mmol/l
fasting blood sugar (FBS)
fasting blood sugar, mmol/l
fasting blood sugar (FBS)
fasting blood sugar, mmol/l
Hemoglobin A1c (HbA1c)
Glycated hemoglobin, mmol/mol
Hemoglobin A1c (HbA1c)
Glycated hemoglobin, mmol/mol
Hemoglobin A1c (HbA1c)
Glycated hemoglobin, mmol/mol
Blood lipids
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, mmol/L
Blood lipids
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, mmol/L
Blood lipids
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, mmol/L
Sensitive C-reactive protein (CRP)
Measurement of inflammation and infection, mmol/L
Sensitive C-reactive protein (CRP)
Measurement of inflammation and infection, mmol/L
Sensitive C-reactive protein (CRP)
Measurement of inflammation and infection, mmol/L
Complete blood count
The number of leukocytes, platelets and erythrocytes per unit volume in a sample of venous blood. Includes measurement of the hemoglobin, hematocrit and erythrocyte indices.
Complete blood count
The number of leukocytes, platelets and erythrocytes per unit volume in a sample of venous blood. Includes measurement of the hemoglobin, hematocrit and erythrocyte indices.
Complete blood count
The number of leukocytes, platelets and erythrocytes per unit volume in a sample of venous blood. Includes measurement of the hemoglobin, hematocrit and erythrocyte indices.
Negative effects
Self constructed question regarding if participants have had any negative effects of treatment: 1) Have you experienced any negative effects from the treatment 2) If yes, please specify:
The Client Satisfaction Questionnaire-8 (CSQ-8)
Self rated satisfaction of treatment. Minimum value 8, maximum value 32 where higher values indicate greater satisfaction with the treatment.
The Credibility/Expectancy Questionnaire (CEQ)
Self rated Credibility of treatment. Minimum value 3, maximum value 27 for each factor, where higher values indicate greater Credibility/Expectancy of the treatment.
Difficulties in Emotion Regulation Scale, Brief Version (DERS-16)
Self rated difficulties in emotion regulation. The sum ranges from 16 to 80, where higher levels indicate greater difficulty in emotion regulation.
Difficulties in Emotion Regulation Scale, Brief Version (DERS-16)
Self rated difficulties in emotion regulation. The sum ranges from 16 to 80, where higher levels indicate greater difficulty in emotion regulation.
Difficulties in Emotion Regulation Scale, Brief Version (DERS-16)
Self rated difficulties in emotion regulation. The sum ranges from 16 to 80, where higher levels indicate greater difficulty in emotion regulation.
Time Line follow back (TLFB)
Interview regarding alcohol and/or drug intake, measuring number of days with alcohol/drug consumption.
Time Line follow back (TLFB)
Interview regarding alcohol and/or drug intake, measuring number of days with alcohol/drug consumption.
Time Line follow back (TLFB)
Interview regarding alcohol and/or drug intake, measuring number of days with alcohol/drug consumption.
The Alcohol Use Disorders Identification Test (Audit - C)
AUDIT-C is an alcohol screen that can help identify patients who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The AUDIT-C is scored on a scale of 0-12 (scores of 0 reflect no alcohol use). In men, a score of 4 or more is considered positive; in women, a score of 3 or more is considered positive. Generally, the higher the AUDIT-C score, the more likely it is that the patient's drinking is affecting his/her health and safety.
The Alcohol Use Disorders Identification Test (Audit - C)
AUDIT-C is an alcohol screen that can help identify patients who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The AUDIT-C is scored on a scale of 0-12 (scores of 0 reflect no alcohol use). In men, a score of 4 or more is considered positive; in women, a score of 3 or more is considered positive. Generally, the higher the AUDIT-C score, the more likely it is that the patient's drinking is affecting his/her health and safety.
The Alcohol Use Disorders Identification Test (Audit - C)
AUDIT-C is an alcohol screen that can help identify patients who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The AUDIT-C is scored on a scale of 0-12 (scores of 0 reflect no alcohol use). In men, a score of 4 or more is considered positive; in women, a score of 3 or more is considered positive. Generally, the higher the AUDIT-C score, the more likely it is that the patient's drinking is affecting his/her health and safety.

Full Information

First Posted
July 7, 2023
Last Updated
October 5, 2023
Sponsor
Region Stockholm
Collaborators
Karolinska Institutet
search

1. Study Identification

Unique Protocol Identification Number
NCT06012149
Brief Title
Braining: Implementation of Physical Exercise for Patients in Specialist Psychiatry
Official Title
Braining: Implementation of Physical Exercise for Patients in Specialist Psychiatry, Efficacy Evaluation in a Randomized Controlled Multicentre Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 27, 2023 (Actual)
Primary Completion Date
September 2025 (Anticipated)
Study Completion Date
September 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Region Stockholm
Collaborators
Karolinska Institutet

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this clinical trial is to compare Braining, a physical exercise lifestyle intervention in psychiatric care, with structured advice on physical exercise. The main questions are: does Braining lead to increased physical exercise compared to structured advice on physical exercise? what effect does Braining have on mental and physical health, quality of life and functional level compared to structured advice on physical exercise? The participants will join a twelve weeks long study period with clinician led exercise classes up to three times per week. Before and after the study period they will leave blood tests, take part in a mental and physical examination and fill in assessment scales. To measure physical activity, the participants will carry an accelerometer, a device that measures steps and acceleration. After six and twelve months, the participants take part in the same measurements. The control group takes parts in the same measurements and follow up, but instead of having clinician led exercise classes, they will exercise on their own during the twelve weeks study period.
Detailed Description
Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training sessions and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan. Braining is unique in that it: Includes trained psychiatric clinical staff exercising together with patients from both out- and inpatient ward units in daily, moderate to vigorous aerobic group training sessions is included in regular healthcare fee, (free of charge) includes a motivational and educational visit (as a group seminar or as an individual visit) at the start and end of a twelve-week exercise intervention includes regular measurements (self-assessment questionnaires, blood samples, physical and mental health examination and education before and after the twelve-week exercise intervention) offers short individual motivating visits before every training session, including assessment of day shape and fitness to participate. This study will be a multi-center study performed at 5 psychiatric outpatient units in Region Stockholm. Patients with symptoms of depression and/or anxiety who are not physically active in accordance with WHO recommendations will be invited to participate in the study. The research questions are: Does Braining increase the amount of completed physical training (PT) compared to structured advice on physical exercise (advice on PT according to guidelines)? What effect does Braining have on the mental and physical health, quality of life and functional level of participating patients compared to structured advice on physical exercise? Examined from the following points of view: psychiatric symptoms, such as depression, anxiety, insomnia, emotional regulation? somatic symptoms, such as blood pressure, resting heart rate, BMI, waist measurement, presence of somatic co-morbidity? How do participants rate Braining and structured advice on physical exercise regarding: Satisfaction with treatment Credibility of treatment Negative effects Is Braining a cost-effective intervention? Participants will be randomized to supplementary treatment with Braining or structured advice on physical activity. Braining and advice on physical activity will be compared after a 12-week training period. Measurements of the participants´ psychiatric and somatic health are carried out before the treatment, after 4, 8 and 12 weeks and 6 and 12 months after the end of treatment. Effects of the treatment are examined via validated self-assessment forms, as well as somatic examination with a focus on metabolic status. Venous blood samples are taken before and after the 12-week training period, as well as 6 and 12 months after the end of the training period to investigate changes in metabolic status. In a sub study on a smaller number of participants the researchers will analyze associations with biological factors such as genetic or epigenetic factors, metabolic factors, stress hormone levels, trace elements, degree of inflammation and other biological markers of health and disease that can be measured in ordinary blood tests, e.g. through "Omik" design. Physical activity will be measured by self assessment scales, accelerometer and by number of performed Braining classes. Data analysis: Continuous data will be analyzed using mixed effects models or t-test, nominal data analyzed mainly with chi2 test. In mixed effects models of differences between groups the interaction effect of group and time will be the central estimate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mental Disorders
Keywords
physical exercise, mental disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A randomized controlled superiority trial evaluating if the new method Braining is superior to structured advice on physical activity, concerning increasing physical activity. The trial is a multicenter study conducted at 3-6 sites. Participants are individually randomized in blocks of 2-4 at each site.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
208 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Braining
Arm Type
Experimental
Arm Description
A 12 week program where participants are encouraged to participate in physical exercise at the psychiatric unit.
Arm Title
Structured advice on physical activity
Arm Type
Active Comparator
Arm Description
Health interview and a 12 week program where participants are encouraged to engage in physical exercise outside the psychiatric setting.
Intervention Type
Behavioral
Intervention Name(s)
Braining
Intervention Description
A 12 week program where participants are encouraged to participate in physical exercise at the psychiatric unit.
Intervention Type
Behavioral
Intervention Name(s)
Structured advice on physical activity
Other Intervention Name(s)
Advice on physical activity
Intervention Description
A 12 week program where participants are encouraged to engage in physical exercise
Primary Outcome Measure Information:
Title
Physical activity
Description
Objectively measured physical activity. Total physical activity measured in accelerometer-counts and translated into minutes/day spent in inactivity, low, moderate and vigorous intensity.
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Patient Health Questionnaire 9 (PHQ-9)
Description
Self rated depressive symptoms. Minimum value 0, maximum value 27, where higher values indicate more depressive symptoms.
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Secondary Outcome Measure Information:
Title
Physical activity
Description
Objectively measured physical activity. Total physical activity measured in accelerometer-counts and translated into minutes/day spent in inactivity, low, moderate and vigorous intensity.
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Physical activity
Description
Objectively measured physical activity. Total physical activity measured in accelerometer-counts and translated into minutes/day spent in inactivity, low, moderate and vigorous intensity.
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Self reported physical activity
Description
Self-reported physical activity: Total physical activity as Metabolic Energy Turnover (MET)hours/week and three level categories (low, moderate and high).
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Self reported physical activity
Description
Self-reported physical activity: Total physical activity as Metabolic Energy Turnover (MET)hours/week and three level categories (low, moderate and high).
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Self reported physical activity
Description
Self-reported physical activity: Total physical activity as Metabolic Energy Turnover (MET)hours/week and three level categories (low, moderate and high).
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Patient Health Questionnaire 9 (PHQ-9)
Description
Self rated depressive symptoms. Minimum value 0, maximum value 27, where higher values indicate more depressive symptoms.
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Patient Health Questionnaire 9 (PHQ-9)
Description
Self rated depressive symptoms. Minimum value 0, maximum value 27, where higher values indicate more depressive symptoms.
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Generalised Anxiety Disorder 7-item scale (GAD-7)
Description
Self rated anxiety symptoms. Minimum value 0, maximum value 21, where higher values indicate more anxiety symptoms.
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Generalised Anxiety Disorder 7-item scale (GAD-7)
Description
Self rated anxiety symptoms. Minimum value 0, maximum value 21, where higher values indicate more anxiety symptoms.
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Generalised Anxiety Disorder 7-item scale (GAD-7)
Description
Self rated anxiety symptoms. Minimum value 0, maximum value 21, where higher values indicate more anxiety symptoms.
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Insomnia Severity Index (ISI)
Description
Self rated insomnia symptoms. Minimum value 0, maximum value 28, where higher values indicate more insomnia symptoms.
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Insomnia Severity Index (ISI)
Description
Self rated insomnia symptoms. Minimum value 0, maximum value 28, where higher values indicate more insomnia symptoms.
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Insomnia Severity Index (ISI)
Description
Self rated insomnia symptoms. Minimum value 0, maximum value 28, where higher values indicate more insomnia symptoms.
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
The Work and Social Adjustment Scale (WSAS)
Description
The WSAS is a simple, reliable and valid measure of impaired functioning. It is a sensitive and useful outcome measure offering the potential for readily interpretable comparisons across studies and disorders. The maximum score of the WSAS is 40, lower scores are better. The 5 items are scored 0-8 ranging from Not at-all-Slightly-Definitely-Markedly-Very-severely
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
The Work and Social Adjustment Scale (WSAS)
Description
The WSAS is a simple, reliable and valid measure of impaired functioning. It is a sensitive and useful outcome measure offering the potential for readily interpretable comparisons across studies and disorders. The maximum score of the WSAS is 40, lower scores are better. The 5 items are scored 0-8 ranging from Not at-all-Slightly-Definitely-Markedly-Very-severely
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
The Work and Social Adjustment Scale (WSAS)
Description
The WSAS is a simple, reliable and valid measure of impaired functioning. It is a sensitive and useful outcome measure offering the potential for readily interpretable comparisons across studies and disorders. The maximum score of the WSAS is 40, lower scores are better. The 5 items are scored 0-8 ranging from Not at-all-Slightly-Definitely-Markedly-Very-severely
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
EUROQOL 5 dimensions (EQ5D)
Description
The EQ-5D [1] is an instrument that consists of two parts and measures health-related quality of life, regardless of disease profile. The instrument measures the general state of health within five dimensions. Values are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead. An EQ-5D value is also sometimes known as an 'index', 'score' or 'utility'.
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
EUROQOL 5 dimensions (EQ5D)
Description
The EQ-5D [1] is an instrument that consists of two parts and measures health-related quality of life, regardless of disease profile. The instrument measures the general state of health within five dimensions. Values are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead. An EQ-5D value is also sometimes known as an 'index', 'score' or 'utility'.
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
EUROQOL 5 dimensions (EQ5D)
Description
The EQ-5D [1] is an instrument that consists of two parts and measures health-related quality of life, regardless of disease profile. The instrument measures the general state of health within five dimensions. Values are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead. An EQ-5D value is also sometimes known as an 'index', 'score' or 'utility'.
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Quality Adjusted Life Years (QALY)
Description
The quality-adjusted life year (QALY) is a generic measure of disease burden, including both the quality and the quantity of life lived. It is used in economic evaluation to assess the value of medical interventions. One QALY equates to one year in perfect health. QALY scores range from 1 (perfect health) to 0 (dead).
Time Frame
Change from 12-0 months pre intervention to 0-12 months post intervention
Title
The incremental cost-effectiveness (ICER)
Description
The incremental cost-effectiveness ratio (ICER) is a statistic used in cost-effectiveness analysis to summarise the cost-effectiveness of a health care intervention. It is defined by the difference in cost between two possible interventions, divided by the difference in their effect. It represents the average incremental cost associated with 1 additional unit of the measure of effect. Costs will be described in monetary units, while effects will be measured in terms of health status.
Time Frame
Change from 12-0 months pre intervention to 0-12 months post intervention
Title
Blood pressure
Description
systolic and diastolic, mmHg
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Blood pressure
Description
systolic and diastolic, mmHg
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Blood pressure
Description
systolic and diastolic, mmHg
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Body mass index (BMI)
Description
Weight in kg divided by the square of height in m
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Body mass index (BMI)
Description
Weight in kg divided by the square of height in m
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Body mass index (BMI)
Description
Weight in kg divided by the square of height in m
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Waist circumference
Description
Waist circumference, cm
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Waist circumference
Description
Waist circumference, cm
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Waist circumference
Description
Waist circumference, cm
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Heart rate (HR)
Description
Heart rate, beats per minute, resting state
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Heart rate (HR)
Description
Heart rate, beats per minute, resting state
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Heart rate (HR)
Description
Heart rate, beats per minute, resting state
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
fasting blood sugar (FBS)
Description
fasting blood sugar, mmol/l
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
fasting blood sugar (FBS)
Description
fasting blood sugar, mmol/l
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
fasting blood sugar (FBS)
Description
fasting blood sugar, mmol/l
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Hemoglobin A1c (HbA1c)
Description
Glycated hemoglobin, mmol/mol
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Hemoglobin A1c (HbA1c)
Description
Glycated hemoglobin, mmol/mol
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Hemoglobin A1c (HbA1c)
Description
Glycated hemoglobin, mmol/mol
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Blood lipids
Description
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, mmol/L
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Blood lipids
Description
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, mmol/L
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Blood lipids
Description
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, mmol/L
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Sensitive C-reactive protein (CRP)
Description
Measurement of inflammation and infection, mmol/L
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Sensitive C-reactive protein (CRP)
Description
Measurement of inflammation and infection, mmol/L
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Sensitive C-reactive protein (CRP)
Description
Measurement of inflammation and infection, mmol/L
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Complete blood count
Description
The number of leukocytes, platelets and erythrocytes per unit volume in a sample of venous blood. Includes measurement of the hemoglobin, hematocrit and erythrocyte indices.
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Complete blood count
Description
The number of leukocytes, platelets and erythrocytes per unit volume in a sample of venous blood. Includes measurement of the hemoglobin, hematocrit and erythrocyte indices.
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Complete blood count
Description
The number of leukocytes, platelets and erythrocytes per unit volume in a sample of venous blood. Includes measurement of the hemoglobin, hematocrit and erythrocyte indices.
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Negative effects
Description
Self constructed question regarding if participants have had any negative effects of treatment: 1) Have you experienced any negative effects from the treatment 2) If yes, please specify:
Time Frame
12 weeks post inclusion
Title
The Client Satisfaction Questionnaire-8 (CSQ-8)
Description
Self rated satisfaction of treatment. Minimum value 8, maximum value 32 where higher values indicate greater satisfaction with the treatment.
Time Frame
12 weeks post inclusion
Title
The Credibility/Expectancy Questionnaire (CEQ)
Description
Self rated Credibility of treatment. Minimum value 3, maximum value 27 for each factor, where higher values indicate greater Credibility/Expectancy of the treatment.
Time Frame
2 weeks post inclusion
Title
Difficulties in Emotion Regulation Scale, Brief Version (DERS-16)
Description
Self rated difficulties in emotion regulation. The sum ranges from 16 to 80, where higher levels indicate greater difficulty in emotion regulation.
Time Frame
Change from Pre intervention start to 12 weeks post intervention start
Title
Difficulties in Emotion Regulation Scale, Brief Version (DERS-16)
Description
Self rated difficulties in emotion regulation. The sum ranges from 16 to 80, where higher levels indicate greater difficulty in emotion regulation.
Time Frame
Change from Pre intervention start to 6 months post intervention start
Title
Difficulties in Emotion Regulation Scale, Brief Version (DERS-16)
Description
Self rated difficulties in emotion regulation. The sum ranges from 16 to 80, where higher levels indicate greater difficulty in emotion regulation.
Time Frame
Change from Pre intervention start to 12 months post intervention start
Title
Time Line follow back (TLFB)
Description
Interview regarding alcohol and/or drug intake, measuring number of days with alcohol/drug consumption.
Time Frame
Change from Pre intervention start to 12 weeks post intervention start.
Title
Time Line follow back (TLFB)
Description
Interview regarding alcohol and/or drug intake, measuring number of days with alcohol/drug consumption.
Time Frame
Change from Pre intervention start to 6 months post intervention start.
Title
Time Line follow back (TLFB)
Description
Interview regarding alcohol and/or drug intake, measuring number of days with alcohol/drug consumption.
Time Frame
Change from Pre intervention start to 12 months post intervention start.
Title
The Alcohol Use Disorders Identification Test (Audit - C)
Description
AUDIT-C is an alcohol screen that can help identify patients who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The AUDIT-C is scored on a scale of 0-12 (scores of 0 reflect no alcohol use). In men, a score of 4 or more is considered positive; in women, a score of 3 or more is considered positive. Generally, the higher the AUDIT-C score, the more likely it is that the patient's drinking is affecting his/her health and safety.
Time Frame
Change from Pre intervention start to 12 weeks post intervention start.
Title
The Alcohol Use Disorders Identification Test (Audit - C)
Description
AUDIT-C is an alcohol screen that can help identify patients who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The AUDIT-C is scored on a scale of 0-12 (scores of 0 reflect no alcohol use). In men, a score of 4 or more is considered positive; in women, a score of 3 or more is considered positive. Generally, the higher the AUDIT-C score, the more likely it is that the patient's drinking is affecting his/her health and safety.
Time Frame
Change from Pre intervention start to 6 months post intervention start.
Title
The Alcohol Use Disorders Identification Test (Audit - C)
Description
AUDIT-C is an alcohol screen that can help identify patients who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The AUDIT-C is scored on a scale of 0-12 (scores of 0 reflect no alcohol use). In men, a score of 4 or more is considered positive; in women, a score of 3 or more is considered positive. Generally, the higher the AUDIT-C score, the more likely it is that the patient's drinking is affecting his/her health and safety.
Time Frame
Change from Pre intervention start to 12 months post intervention start.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient at one of the psychiatric units Exclusion Criteria: Physically active with moderate to vigorous physical activity above recommendations from World Health Organization (WHO) during the last 4 weeks Severe mental disorder such as ongoing mania, psychosis, and conditions when high risk of suicide or high risk of violence available according to the assessment of psychiatric staff at the unit. Medical conditions such as heart or lung disease, infection, withdrawal, where heart rate-increasing physical activity is considered contraindicated due to Medical reasons. Physical disability that makes it impossible to move independently to the gym and performing the indicated exercise in the training sessions. Mental disability which means that you can not participate in group training. Difficulty speaking or understanding the Swedish language. Ongoing heavy substance use.
Facility Information:
Facility Name
Region Stockholm, Psykiatri Sydväst (Psychiatric Clinic Psychiatry Southwest)
City
Stockholm
ZIP/Postal Code
14186
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Åsa Anger, MD
Email
asa.susanna.anger@ki.se
First Name & Middle Initial & Last Name & Degree
Anna Wallerblad, MD
Email
anna.wallerblad@yahoo.com
First Name & Middle Initial & Last Name & Degree
Lina Martinsson, PhD
Facility Name
Andreashuset
City
Stockholm
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rebecka Broman
Email
rebecka.broman@regionstockholm.se
Facility Name
Läkemedel och hälsa
City
Stockholm
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rebecka Broman
Email
rebecka.broman@regionstockholm.se
Facility Name
Region Stockholm, Liljeholmsberget
City
Stockholm
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Åsa Anger, MD
Phone
+46736553128
Email
asa.anger@regionstockholm.se
First Name & Middle Initial & Last Name & Degree
Lina Martinsson, PhD
First Name & Middle Initial & Last Name & Degree
Sigrid Salomonsson, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Braining: Implementation of Physical Exercise for Patients in Specialist Psychiatry

We'll reach out to this number within 24 hrs